Psychiatry Research
Volume 111, Issue 1 , Pages 87-92 , 5 August 2002

A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia

  • Rita M Condren

      Affiliations

    • Neuroscience Department, St. Vincent's Hospital, Richmond Road, Fairview, Dublin 3, Ireland
    • ,
  • Neda Sharifi

      Affiliations

    • Endocrinology Department, Beaumont Hospital, Beaumont Road, Dublin 9, Ireland
    • ,
  • Jogin H Thakore

      Affiliations

    • Neuroscience Department, St. Vincent's Hospital, Richmond Road, Fairview, Dublin 3, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353-1-837-5101; fax: +353-1-884-2450

Received 24 August 2001 ,Revised 26 March 2002 ,Accepted 5 April 2002.

References 

  1. American Psychiatric Association, 1994. Diagnostic and statistical Manual of Mental Disorders, 4th ed. American Psychiatric Press, Washington, DC.
  2. Annuziato L. Regulation of the tuberoinfundibular and nigrostriatal systems. Neuroendocrinology. 1979;29:66–73
  3. Bell CJ, Malizia AL, Nutt DJ. The neurobiology of social phobia. European Archives of Psychiatry and Clinical Neuroscience. 1999;249(Suppl. 1):S11–S18
  4. Brunello N, den Boer JA, Judd LL, Kasper S, Kelsey JE, Lader M, et al. Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. Journal of Affective Disorders. 2000;60:61–74
  5. Boockfor FR, Hoeffler JP, Frawley LS. Cultures of GH3 cells are functionally heterogeneous: thyrotropin-releasing hormone, estradiol and cortisol cause some reciprocal shifts in the proportions of growth hormone and prolactin secretors. Endocrinology. 1985;117:418–420
  6. Closse A, Camps M, Wanner A, Palacios JM. In vivo labelling of brain dopamine D2 receptors using the high affinity specific D2 agonist [3H]-CV205-502. Brain Research. 1988;440:123–132
  7. Davidson JRT, Hughes DC, George LK, Blazer DG. The boundary of social phobia. Archives of General Psychiatry. 1994;51:975–983
  8. Dinan TG, Scott LV. The role of cortisol in spontaneous and stimulated prolactin release. Journal of Basic Clinical Physiology and Pharmacology. 1996;7:45–57
  9. Dinan TG, Scott LV, Thakore JH, Naesdal J, Keeling PWN. Impact of cortisol on buspirone stimulated prolactin release: a double-blind placebo-controlled study. Psychoneuroendocrinology. 2001;26:751–756
  10. Emmanuel NP, Lydiard RB, Ballenger JC. Treatment of social phobia with bupropion (letter). Journal of Clinical Psychopharmacology. 1991;11:276–277
  11. Evans RM, Birnbeg NC, Rosenfeld MG. Glucocorticoid and thyroid hormones transcriptionally regulate growth hormone gene expression. Proceedings of the National Academy of Sciences USA. 1982;79:7659–7663
  12. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., 1995. Structured Clinical Interview for DSM-IV Axis 1 Disorders, Patient Edition (SCID-P), version 2. New York State Psychiatric Institute, Biometrics Research, New York.
  13. Gaillard RC, Brownell J. Hormonal effects of CV205-502, a novel octahydrobenzo[g] quinoline with potent dopamine agonist properties. Life Sciences. 1988;43:1355–1362
  14. Gaillard RC, Nordmann R, Petcher TJ, Brownell J. A novel octahydrobenzo [g] quinoline, CV 205-502, with potent dopamine agonist properties. In:  Molinatti GM,  Martini L editor. Endocrinology ‘85. Amsterdam: Elsevier; 1986;p. 305–308
  15. Gaillard RC, Abeywickrama K, Brownell J, Muller AF. Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test. Journal of Clinical Endocrinology and Metabolism. 1989;68:329–335
  16. Guy W. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Department of Health, Education and Welfare; 1976;p. 217–222
  17. Heimberg RG, Hope DA, Dodge CS, Becker RE. DSM-III-R subtypes of social phobia. Comparison of generalized social phobics and public speaking phobics. Journal of Nervous and Mental Disease. 1990;178:172–179
  18. Hwang DR, Kegeles LS, Laruelle M. (−)N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2)receptors. Nuclear Medicine and Biology. 2000;27:533–539
  19. Johnson MR, Lydiard RB, Zealberg JJ, Fossey MD, Ballenger JC. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biological Psychiatry. 1994;36:425–427
  20. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51:8–19
  21. Lamberts SWJ, Macleod RM. Regulation of prolactin secretion at the level of the lactotroph. Physiological Reviews. 1990;70:279–318
  22. Levin AP, Saoud JB, Strauman T, Gorman JM, Fyer AJ, Crawford R, et al. Responses of ‘generalized’ and ‘discrete’ social phobics during public speaking. Journal of Anxiety Disorders. 1993;7:207–221
  23. Liebowitz MR, Campeas R, Hollander E. Possible dopamine dysregulation in social phobia and atypical depression. Psychiatry Research. 1987;22:89–90
  24. Liebowitz MR. Social phobia. Modern Problems in Pharmacopsychiatry. 1987;22:141–173
  25. Martel FL, Hayward C, Lyons DM, Sanborn K, Varady S, Schatzberg AF. Salivary cortisol levels in socially phobic adolescent girls. Depression and Anxiety. 1999;10:25–27
  26. Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. American Journal of Psychiatry. 2001;10:1558–1567
  27. Mikkelsen EJ, Deltor J, Cohen DJ. School avoidance and social phobia triggered by haloperidol in patients with Tourette's syndrome. American Journal of Psychiatry. 1981;138:1572–1576
  28. Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H, et al. Six-month prevalence of psychiatric disorders in three communities: 1980–1982. Archives of General Psychiatry. 1984;41:959–967
  29. Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, et al. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. European Journal of Endocrinology. 2000;143:615–621
  30. Nutt DJ, Bell CJ, Malizia AL. Brain mechanisms of social anxiety disorder. Journal of Clinical Psychiatry. 1998;59(Suppl 17):4–9
  31. Potts NL, Davidson JRT, Krishnan KR, Doriswamy PM, Ritchie JC. Levels of urinary free cortisol in social phobia. Journal of Clinical Psychiatry. 1992;52:41–42
  32. Rohmer V, Freneau E, Morange I, Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Annales d'endocrinologie. 2000;61:411–417
  33. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin S-H, Laruelle M. Low dopamine D2 receptor binding potential in social phobia. American Journal of Psychiatry. 2000;157:457–459
  34. Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF. Quinagolide in the management of prolactinoma. Pituitary. 2000;3:239–249
  35. Sheehan D. In: The Anxiety Disease. New York: Scribner; 1983;p. 148–149
  36. Statistical Graphics Corporation, 1993. Version 7.0. Statgraphics. Manguistics Inc., Cambridge, MA.
  37. Stein MB. Neurobiological perspectives on social phobia: from affiliation to zoology. Biological Psychiatry. 1998;44:1277–1285
  38. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. American Journal of Psychiatry. 1990;147:217–220
  39. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community study of social anxiety. American Journal of Psychiatry. 1994;152:408–412
  40. Tancer ME, Mailman RB, Stein MB, Mason GA, Carson SW, Golden RN. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety. 1994/1995;1:216–223
  41. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. American Journal of Psychiatry. 1997;154:239–242
  42. Uhde TW, Tancer ME, Gelernter CS, Vittone BJ. Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. Journal of Affective Disorders. 1994;30:155–161
  43. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. Journal of Neural Transmission [P-D Sect]. 1991;3:151–201
  44. Young AH, Sharpley AL, Campling GM, Hockney RA, Cowen PJ. Effects of hydrocortisone on brain 5HT function and sleep. Journal of Affective Disorders. 1994;32:139–146

PII: S0165-1781(02)00103-8

Psychiatry Research
Volume 111, Issue 1 , Pages 87-92 , 5 August 2002

Article Tools

* Image Usage & Resolution